ciprofloxacin orion 250 mg tabletti, kalvopäällysteinen
orion corporation - ciprofloxacin hydrochloride - tabletti, kalvopäällysteinen - 250 mg - siprofloksasiini
ciprofloxacin orion 500 mg tabletti, kalvopäällysteinen
orion corporation - ciprofloxacin hydrochloride - tabletti, kalvopäällysteinen - 500 mg - siprofloksasiini
ciprofloxacin orion 750 mg tabletti, kalvopäällysteinen
orion corporation - ciprofloxacin hydrochloride - tabletti, kalvopäällysteinen - 750 mg - siprofloksasiini
ciprofloxacin ratiopharm 250 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - ciprofloxacin hydrochloride anhydrous - tabletti, kalvopäällysteinen - 250 mg - siprofloksasiini
ciprofloxacin ratiopharm 500 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - ciprofloxacin hydrochloride anhydrous - tabletti, kalvopäällysteinen - 500 mg - siprofloksasiini
ciprofloxacin ratiopharm 750 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - ciprofloxacin hydrochloride anhydrous - tabletti, kalvopäällysteinen - 750 mg - siprofloksasiini
ciprofloxacin krka 250 mg tabletti, kalvopäällysteinen
krka sverige ab - ciprofloxacin hydrochloride - tabletti, kalvopäällysteinen - 250 mg - siprofloksasiini
ciprofloxacin krka 500 mg tabletti, kalvopäällysteinen
krka sverige ab - ciprofloxacin hydrochloride - tabletti, kalvopäällysteinen - 500 mg - siprofloksasiini
ciprofloxacin krka 750 mg tabletti, kalvopäällysteinen
krka sverige ab - ciprofloxacin hydrochloride - tabletti, kalvopäällysteinen - 750 mg - siprofloksasiini
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.